Stock Analiz

Kiniksa Pharmaceuticals International, plc (KNSA) financials: revenue, earnings and cash flow

Fiscal 2017–2025 + TTM · from SEC filings · data as of November 16, 2026

Summary

Net income in fiscal 2025 was $59M, a net margin of 8.7%; the best year in this period was 2022 with $183M.

Over the twelve months to September 30, 2026, revenue was $946M and net income $110M.

Free cash flow was $136M in fiscal 2025 and positive in 4 of the 9 years shown.

The diluted share count rose 4264% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2021: $39M20212022: $220M20222023: $270M20232024: $423M20242025: $678M2025$678M
Net income
2017: -$65M172018: -$103M182019: -$162M192020: -$161M202021: -$158M212022: $183M222023: $14M232024: -$43M242025: $59M25$59M
Free cash flow
2017: -$50M172018: -$86M182019: -$162M192020: -$137M202021: -$127M212022: $6M222023: $13M232024: $25M242025: $136M25$136M
EPS (diluted)
2017: $-35.85172018: $-3.49182019: $-2.99192020: $-2.61202021: $-2.30212022: $2.60222023: $0.20232024: $-0.60242025: $0.7525$0.75

Income statement

Fiscal yearTTM202520242023202220212020201920182017
Revenue$946M$678M$423M$270M$220M$39M————
Gross profit$853M$600M$362M$237M$197M$29M————
Operating income$130M$77M-$46M-$25M$10M-$157M-$157M-$170M-$108M-$65M
Net income$110M$59M-$43M$14M$183M-$158M-$161M-$162M-$103M-$65M
EPS (diluted)$1.31$0.75$-0.60$0.20$2.60$-2.30$-2.61$-2.99$-3.49$-35.85
R&D$136M$97M$112M$76M$65M$99M$112M$135M$87M$56M
Revenue growth—+60.1%+56.6%+22.7%+471.2%—————

Cash flow

Fiscal yearTTM202520242023202220212020201920182017
Operating cash flow$199M$138M$26M$13M$6M-$126M-$137M-$158M-$81M-$50M
Capital spending-$2M-$2M-$277000-$130000-$105000-$415000-$283000-$3M-$5M-$69000
Free cash flow$197M$136M$25M$13M$6M-$127M-$137M-$162M-$86M-$50M
Dividends paid—$0—$0$0$0$0$0$0$0
Buybacks——————————
Stock-based pay$45M$37M$31M$27M$25M$25M$21M$15M$6M$897000

Balance sheet

Fiscal yearTTM202520242023202220212020201920182017
Cash—$414M$244M$206M$191M$182M$323M$233M$307M$46M
Debt—$9M$10M$12M$6M$6M$7M$3M$0$0
Equity—$568M$438M$439M$396M$185M$312M$225M$279M-$90M
Total assets—$764M$581M$526M$460M$233M$349M$255M$322M$47M
Shares (diluted)85M79M71M72M70M69M62M54M30M2M

Margins and returns

Fiscal yearTTM202520242023202220212020201920182017
Gross margin90.2%88.5%85.6%87.6%89.6%76.4%————
Operating margin13.8%11.4%-10.8%-9.3%4.4%-406.4%————
Net margin11.6%8.7%-10.2%5.2%83.3%-409.7%————
FCF margin20.8%20.1%6.0%4.9%2.6%-328.8%————
ROIC—8.9%-8.0%-4.4%1.9%-64.8%-39.0%-73.6%-38.6%—
ROE—10.4%-9.8%3.2%46.3%-85.4%-51.7%-71.8%-37.0%72.3%

Frequently asked questions

What is Kiniksa Pharmaceuticals International’s annual revenue?

$678M in fiscal 2025 and $946M over the twelve months to September 30, 2026.

How much profit does Kiniksa Pharmaceuticals International make?

Net income was $59M in fiscal 2025 (net margin 8.7%).

Is Kiniksa Pharmaceuticals International’s revenue growing?

Yes: revenue rose 60.1% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.